The $471 Billion Opportunity for GLP-1s
The pharmaceutical landscape is no stranger to innovation and transformation, but few breakthroughs have made waves like GLP-1s. Initially developed...
Tom Davies, PharmD's Posts
From Concept to Cure: Understanding the Drug Pipeline and its Cost Implications
Drugs progress through the testing cycle by passing through incrementally more complex and expensive phases. To reach FDA approval, a...
After 20 Years of Humira Prescriptions, Therapeutic Interchange Programs Give Employers Much-Needed Options
Self-funded plan sponsors face a growing number of expensive anti-inflammatory and dermatology prescriptions, and they need a benefit advisor who...
Reaching Towards Remission: How Diabetes Treatment Protects Members from Complications
A diabetes diagnosis can feel like a heavy burden for the patient, their family, and their plan sponsor — and...
From Insulin to Advertising, Understanding the Drivers of Diabetes Drug Costs
A serious condition that frequently requires lifelong management with one or more medications, diabetes impacts more than 10% of Americans,...
The Scope and Significance of Medication Adherence – Part Three
Medication adherence is one of the most complex patient behaviors. When plan members stop taking medications as directed, it can...
The Scope and Significance of Medication Adherence – Part Two
This is part two of a two-part series on the state of medication adherence in the United States. You can...
The Scope and Significance of Medication Adherence
Medication adherence has an undeniable effect on improving health outcomes and quality and length of life and can be instrumental...
At What Cost: 6 Financially Wasteful Medications
The skyrocketing cost of prescription medications inflicts a financial burden on everyone in the healthcare realm – from consumer to...
